TP53 and primary effusion lymphoma: Pure erythroid leukemia (PEL) is a rare and aggressive subtype of acute myeloid leukemia (AML) and accounts for approximately 1% of all AML diagnoses.[1] However, the 2022 International Consensus Classification (ICC) includes PEL under a broader category of “acute myeloid leukemia with mutated TP53.”[2] PEL frequently presents with complex karyotype and TP53 mutations while its etiology and molecular mechanisms remain unknown.